Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283826 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
A Phase 1 study, sponsored by Atara Biotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 134
- Enrollment target
NCT03283826 is a Phase 1 study that was terminated before completion, run by Atara Biotherapeutics. The registered enrollment target is 134 participants.
The verdict
NCT03283826, a Phase 1 study, was terminated before completion, sponsored by Atara Biotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 134 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by confirmed Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis \[PPMS\] and secondary progressive multiple sclerosis \[SPMS\]).
Interventions
- DRUG Placebo
- BIOLOGICAL ATA188
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2024-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283826
The ClinicalTrials.gov registry entry for NCT03283826 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atara Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03283826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03283826 about?
NCT03283826 is a clinical study titled "Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis". The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by confirmed Expand...
What is the current status of trial NCT03283826?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 134 participants. The study started on 2017-10-19. Estimated completion is 2024-01-17.
What interventions are being tested in trial NCT03283826?
The interventions under investigation include: Placebo (DRUG), ATA188 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03283826?
This trial is sponsored by Atara Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.